nbutanol
fraction
bf
obtain
crude
extract
marin
spong
petromica
citrina
halistanolenrich
fraction
tsh
fraction
isol
compound
halistanol
sulfat
halistanol
sulfat
c
evalu
inhibitori
effect
replic
herp
simplex
viru
type
ko
mar
drug
strain
viral
plaqu
number
reduct
assay
tsh
fraction
effect
replic
si
wherea
compound
si
si
less
activ
activ
fraction
compound
also
assay
determin
viral
multipl
step
upon
act
well
potenti
synergist
effect
activ
detect
mediat
inhibit
viru
attach
penetr
vero
cell
virucid
effect
viru
particl
impair
level
gd
protein
summari
result
suggest
activ
tsh
fraction
detect
possibl
relat
synerg
effect
compound
drug
choic
prophylaxi
treatment
herpex
simplex
viru
hsv
infect
acyclovir
acv
select
inhibit
hsv
dna
replic
low
hostcel
toxic
howev
intens
use
antivir
drug
led
emerg
resist
virus
recent
de
clercq
describ
evolut
antivir
agent
viral
infect
includ
hsv
confirm
search
new
antivir
agent
still
relev
pharmaceut
interest
marin
organ
provid
thousand
new
novel
compound
shown
import
biolog
properti
anticanc
antivir
antiprotozo
antibacteri
activ
context
marin
spong
prolif
sourc
divers
secondari
metabolit
complex
uniqu
structur
use
lead
compound
obtain
new
drug
current
use
clinic
acyclovir
vidarabin
cytarabin
eribulin
mesyl
other
clinic
stage
evalu
hemiasterlin
addit
sever
highli
activ
compound
marin
spong
report
new
biolog
activ
structur
petromica
citrina
porifera
demospongi
belong
marin
spong
genu
occur
brazilian
coast
studi
speci
describ
evalu
differ
pharmacolog
properti
antibacteri
antivir
activ
aqueou
extract
nbutanol
fraction
moreov
restrict
number
chemic
investig
bioactiv
constitu
report
particular
sulfat
steroid
compound
identifi
halistanol
sulfat
recent
research
group
describ
antiherp
activ
nbutanol
fraction
p
citrina
thu
aim
investig
determin
bioguid
studi
activ
compound
respons
activ
detect
previou
screen
antiinfect
potenti
marin
invertebr
seawe
observ
promis
activ
nbutanol
fraction
bf
obtain
ethanol
crude
extract
spong
led
us
perform
studi
goal
isol
bioguid
studi
antiherp
bioactiv
metabolit
present
fraction
first
bf
fraction
submit
sever
sephadex
chromatographi
procedur
yield
five
fraction
pool
base
thinlay
chromatographi
tlc
similar
among
fraction
fraction
show
anti
activ
submit
nmr
analysi
h
nmr
spectrum
display
characterist
signal
presenc
halistanol
sulfat
major
compound
major
compound
isol
column
chromatographi
yield
compound
figur
complet
structur
compound
determin
base
hsqc
hmbc
cosi
spectra
well
esi
mass
spectrometri
comparison
literatur
data
presenc
three
sulfat
group
structur
could
clearli
defin
esi
mass
spectrometri
sulfat
group
also
support
ir
band
cm
addit
h
nmr
spectrum
compound
show
carbinol
signal
h
sl
h
sl
j
hz
h
dt
j
hz
correspond
hsqc
spectrum
signal
c
c
respect
data
togeth
characterist
signal
two
methyl
singlet
ch
ch
suggest
sulfat
sterol
nucleu
structur
side
chain
compound
elucid
analysi
nmr
data
nmr
spectra
show
presenc
side
chain
contain
two
secondari
methyl
j
hz
j
hz
attribut
posit
c
c
also
base
hmbc
data
h
nmr
spectra
reveal
singlet
connect
carbon
suggest
tbutyl
group
side
chain
hmbc
correl
carbon
c
c
c
c
c
proton
confirm
c
c
c
connect
c
therefor
compound
identifi
halistanol
sulfat
steroid
previous
report
marin
spong
halichondria
cf
epipolasi
sp
petromica
ciocalyptoid
haliclona
sp
petromica
citrina
halistanol
sulfat
hs
first
report
fusetani
et
al
work
author
show
c
nmr
data
hs
new
compound
halistanol
sulfat
seri
halistanol
sulfat
h
isol
subsequ
year
nomenclatur
chemic
shift
valu
h
nmr
spectra
side
chain
still
complet
defin
therefor
import
detail
structur
elucid
compound
also
present
compound
also
show
halistanol
steroid
nucleu
signal
shorter
side
chain
infer
nmr
data
togeth
inform
esi
mass
spectrum
structur
well
compound
presenc
sulfat
group
structur
also
support
ir
band
cm
although
hnmr
spectra
compound
display
two
methyl
doublet
side
chain
correspond
c
c
respect
h
nmr
compound
one
doublet
signal
j
hz
correspond
c
methyl
group
addit
h
nmr
data
show
tbutyl
group
end
side
chain
furthermor
two
new
methyl
signal
j
hz
j
hz
identifi
consid
j
valu
proton
could
suggest
presenc
isopropyl
side
chain
thu
base
data
obtain
compound
identifi
halistanol
sulfat
c
steroid
previous
report
pseudoaxinissa
digitata
epilopasi
sp
far
awar
first
report
halistanol
sulfat
c
petromica
citrina
sulfat
sterol
describ
wide
varieti
marin
organ
spong
echinoderm
sever
sterol
great
structur
divers
broad
spectrum
biolog
activ
first
report
compound
halistanol
famili
halistanol
sulfat
isol
marin
spong
halichondria
cf
moorei
bergquist
import
biolog
activ
report
steroid
sulfat
antihiv
effect
cytotox
activ
human
hepatoma
cell
chronic
myelogen
leukemia
cell
afterward
compound
isol
petromica
ciocalyptoid
topsentia
ophiraphidit
show
inhibitori
activ
leishmania
tarentola
wide
spectrum
activ
resist
bacteria
staphylococcu
aureu
staphylococcu
epidermidi
enterococcu
faecali
mycobacterium
fortuitum
neisseria
gonorrhea
thu
far
eight
sulfat
sterol
describ
fundament
nucleu
name
halistanol
sulfat
h
figur
character
function
differ
side
chain
promis
pharmacolog
activ
describ
compound
effect
halistanol
sulfat
f
g
addit
mani
report
differ
member
halistanol
seri
shown
import
pharmacolog
properti
one
first
report
member
seri
ibisterol
sulfat
isol
topsentia
sp
show
antihiv
activ
exampl
halistanoltyp
compound
antivir
activ
weinbersterol
disulf
b
isol
spong
petrosia
weinbergi
exhibit
activ
leukemia
viru
felv
mous
influenza
viru
mous
coronaviru
replic
compound
sulfat
group
describ
antivir
properti
due
antiherpet
activ
shown
bf
fraction
decid
verifi
activ
compound
tsh
fraction
elucid
mode
action
evalu
potenti
antivir
activ
p
citrina
fraction
tsh
fraction
well
isol
compound
perform
ko
strain
use
viral
plaqu
number
reduct
assay
accord
result
obtain
tabl
isol
compound
si
si
show
weak
activ
hand
tsh
fraction
contain
compound
major
constitu
show
promis
activ
si
import
understand
target
mode
action
potenti
use
new
antivir
agent
set
experi
carri
determin
stage
activ
sampl
tsh
fraction
compound
affect
viral
replic
cycl
pretreat
vero
cell
tsh
fraction
compound
three
hour
viral
infect
show
sampl
affect
viral
infect
suggest
exert
protect
effect
infect
process
data
shown
direct
viru
inactiv
activ
test
sampl
absenc
cell
also
evalu
also
observ
tsh
fraction
compound
abl
reduc
infect
concentr
lower
ic
valu
tabl
accord
previou
studi
report
virucid
activ
halistanol
sulfat
f
h
hiv
replic
order
determin
whether
sampl
abl
interfer
earli
event
hsv
infect
effect
attach
penetr
investig
separ
test
sampl
inhibit
viru
attach
penetr
shown
tabl
therefor
inactiv
could
relat
virion
bind
heparan
sulfat
receptor
inhibit
two
earli
stage
viral
replic
natur
sulfat
molecul
sulfat
polysaccharid
also
activ
hiv
replic
inhibit
earli
event
viral
replic
well
document
antivir
potenc
sulfat
compound
depend
degre
sulfat
moreov
becom
clear
antivir
properti
sulfat
compound
simpl
function
detail
structur
featur
also
charg
densiti
instanc
highli
charg
molecul
like
interfer
electrostat
interact
posit
charg
region
viral
glycoprotein
neg
charg
hs
chain
cellsurfac
glycoprotein
receptor
could
explain
blockad
viral
attach
penetr
competit
inhibit
addit
also
test
anti
activ
halistanol
disulf
ds
halistanol
monosulf
ms
data
shown
observ
ds
less
activ
halistanol
sulfat
halistanol
sulfat
c
compound
respect
trisulf
deriv
well
ms
inact
view
fact
result
suggest
tsh
fraction
compound
affect
earli
stage
hsv
replic
also
investig
effect
sampl
protein
express
replic
western
blot
figur
result
show
tsh
fraction
sampl
reduc
express
test
protein
concentrationdepend
manner
nevertheless
immedi
protein
express
ko
strain
reduc
test
sampl
confirm
interfer
earli
event
replic
addit
event
concentrationdepend
inhibit
gb
glycoprotein
synthes
late
phase
replic
also
observ
tsh
fraction
reduc
gd
express
result
suggest
alter
immedi
earli
protein
express
could
affect
express
late
protein
statement
support
find
fontainerodrigu
knipe
demonstr
requir
effici
express
hsv
late
protein
given
fact
tsh
fraction
compound
seem
act
differ
way
acv
potenti
synergist
effect
test
differ
concentr
tabl
result
obtain
suggest
strong
synerg
tsh
fraction
compound
compound
acv
moder
synerg
compound
test
drug
higher
concentr
ic
compound
test
associ
strong
synerg
also
detect
three
test
concentr
relat
combin
slight
moder
antagon
detect
except
associ
acv
tsh
fraction
intermedi
concentr
ic
addit
effect
detect
observ
synerg
sampl
acv
could
explain
fact
sampl
act
differ
step
replic
affect
antiherp
drug
could
consid
interest
result
therefor
import
result
obtain
compound
test
associ
show
detect
antihsv
activ
could
explain
strong
synerg
effect
major
compound
present
tsh
fraction
natur
compound
antiherp
activ
sulfat
polysaccharid
docosanol
oxiresveratrol
alreadi
report
present
synergist
effect
acv
corrobor
result
gener
nmr
experi
perform
bruker
avanc
mhz
instrument
mhz
h
mhz
c
spectra
record
cd
od
use
signal
residu
nondeuter
solvent
intern
refer
mass
spectrometr
analys
perform
use
bruker
microtofq
ii
mass
spectromet
bruker
dalton
billerica
usa
equip
esi
multipoint
mass
calibr
carri
use
mixtur
sodium
format
mz
data
acquisit
process
carri
use
bruker
compass
data
analysi
version
softwar
suppli
instrument
analyt
solut
mgml
prepar
use
methanol
lcm
grade
compound
infus
sourc
use
kd
syring
pump
frozen
spong
g
wet
exhaust
extract
ethanol
three
day
room
temperatur
crude
ethanol
extract
che
filter
ethanol
elimin
reduc
pressur
gummi
residu
suspend
h
extract
success
ethyl
acet
etoac
nbutanol
nbuoh
ml
yield
three
fraction
etoac
eaf
nbuoh
bf
aqueou
residu
ar
respect
next
bf
fraction
g
subject
sephadex
column
chromatographi
mm
mm
use
methanol
meoh
eluent
total
tube
ml
collect
combin
five
fraction
mg
mg
mg
mg
mg
base
silica
gel
thinlay
chromatographi
tlc
similar
fraction
name
tsh
fraction
show
one
spot
tlc
analysi
fraction
forward
hnmr
analysi
prove
mixtur
halistanol
sulfat
compound
halistanol
sulfat
c
compound
major
compound
tsh
fraction
mg
dissolv
methanol
submit
reversedphas
column
chromatographi
mm
mm
pack
stationari
phase
meoh
h
vv
mobil
phase
procedur
result
two
isol
compound
halistanol
sulfat
mg
compound
halistanol
sulfat
c
mg
compound
figur
show
step
purif
ko
strain
faculti
pharmaci
univers
renn
franc
propag
vero
cell
viral
stock
store
titrat
base
plaqu
form
unit
pfu
count
plaqu
assay
previous
describ
vero
atcc
ccl
cell
grown
eagl
minimum
essenti
medium
mem
cultilab
campina
brazil
supplement
fetal
bovin
serum
fb
gibco
carlsbad
ca
usa
uml
penicillin
g
streptomycin
amphotericin
b
cultilab
maintain
humidifi
co
vero
cell
viabil
measur
mtt
tetrazolium
bromidesigmaaldrich
st
loui
mo
usa
briefli
confluent
vero
cell
expos
differ
concentr
sampl
h
incub
cytotox
concentr
cc
one
calcul
concentr
reduc
cell
viabil
compar
untreat
control
viral
plaqu
number
reduct
assay
evalu
antiherp
activ
plaqu
reduct
assay
perform
follow
gener
procedur
describ
silva
et
al
vero
cell
monolay
infect
approxim
pfu
viru
h
overlaid
mem
contain
carboxymethylcellulos
cmc
sigmaaldrich
st
loui
mo
usa
either
presenc
absenc
differ
concentr
sampl
h
incub
cell
fix
stain
naphtol
blueblack
sigmaaldrich
st
loui
mo
usa
plaqu
count
ic
sampl
calcul
concentr
reduc
number
viral
plaqu
compar
untreat
control
acv
use
posit
control
select
index
si
cc
ic
calcul
sampl
test
virucid
assay
mixtur
serial
twofold
dilut
sampl
pfu
serum
free
mem
coincub
min
prior
dilut
mixtur
noninhibitori
concentr
residu
infect
determin
viral
plaqu
number
reduct
assay
describ
pretreat
assay
perform
describ
bettega
et
al
briefli
vero
cell
monolay
pretreat
differ
concentr
sampl
h
prior
viru
infect
wash
cell
infect
pfu
h
infect
cell
wash
overlaid
mem
contain
cmc
incub
h
treat
describ
earlier
viral
plaqu
number
reduct
assay
simultan
treatment
assay
perform
describ
silva
et
al
briefli
pfu
differ
concentr
sampl
ad
concomitantli
vero
cell
h
wash
cell
overlaid
mem
contain
cmc
incub
h
treat
describ
earlier
viral
plaqu
number
reduct
assay
adsorpt
penetr
assay
assay
follow
procedur
describ
silva
et
al
minor
modif
briefli
adsorpt
assay
confluent
vero
cell
prechil
h
infect
pfu
treat
differ
concentr
sampl
incub
h
unabsorb
virus
remov
wash
cold
pb
cell
cover
overlay
medium
temperatur
rais
treat
describ
earlier
viral
plaqu
number
reduct
assay
dextran
sulfat
sigma
use
posit
control
penetr
assay
pfu
adsorb
h
confluent
vero
cell
incub
min
maxim
viru
penetr
cell
treat
differ
concentr
sampl
h
unpenetr
virus
inactiv
warm
citratebuff
ph
min
cell
wash
pb
treat
describ
viral
plaqu
number
reduct
assay
western
blot
analysi
procedur
perform
describ
bertol
et
al
briefli
vero
cell
monolay
infect
moi
h
next
residu
virus
remov
pb
cell
submit
differ
treatment
h
protein
extract
cell
separ
sdspolyacrylamid
gel
electrophoresi
sdspage
transfer
polyvinyliden
difluorid
pvdf
membran
millipor
billerica
usa
block
nonfat
milk
blot
buffer
mm
trishcl
ph
mm
nacl
tween
membran
incub
min
follow
primari
antibodi
goat
monoclon
antibodi
protein
dilut
santa
cruz
biotechnolog
santa
cruz
ca
usa
mous
monoclon
antibodi
protein
dilut
millipor
st
charl
mo
usa
mous
monoclon
antibodi
gd
dilut
santa
cruz
biotechnolog
santa
cruz
ca
usa
mous
monoclon
antibodi
gb
dilut
millipor
st
charl
mo
usa
rabbit
monoclon
antibodi
betaactin
dilut
millipor
st
charl
mo
usa
wash
membran
incub
respect
secondari
antibodi
h
immunoblot
develop
detect
use
pierc
ecl
western
blot
substrat
thermo
scientif
rockford
il
usa
accord
manufactur
instruct
effect
tsh
fraction
compound
combin
acv
compound
evalu
plaqu
reduct
assay
describ
accord
experiment
design
propos
chou
et
al
briefli
sampl
alon
combin
test
fix
ratio
correspond
ic
valu
ie
ic
interact
degre
sampl
base
medianeffect
principl
massact
law
use
calcusyn
softwar
version
biosoft
cambridg
uk
accord
ci
theorem
ci
valu
indic
synerg
addit
effect
antagon
respect
summari
result
suggest
tsh
fraction
compound
present
antiherp
activ
reduct
viral
infect
inhibit
viru
entri
cell
impair
level
gd
protein
relev
select
index
tsh
fraction
content
compound
well
strong
synerg
effect
observ
suggest
detect
antihsv
activ
could
explain
synerg
effect
major
compound
present
tsh
fraction
